Do analysts prefer ATYR or ALEC?

Alector has a consensus price target of $3.63, indicating a potential upside of 57.61%. Given Alector's higher possible upside, analysts clearly believe Alector is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13

Which has higher earnings & valuation, ATYR or ALEC?

aTyr Pharma has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 273.62 -$74.12M -$0.62 N/A Alector $21.05M 12.20 -$142.93M -$1.10 N/A

Is ATYR or ALEC more profitable?

aTyr Pharma has a net margin of 0.00% compared to Alector's net margin of -850.13%. aTyr Pharma's return on equity of -95.89% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% Alector -850.13% -531.03% -44.00%

Does the media favor ATYR or ALEC?

In the previous week, aTyr Pharma and aTyr Pharma both had 1 articles in the media. Alector's average media sentiment score of 1.67 beat aTyr Pharma's score of 0.00 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer ATYR or TNXP?

Tonix Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 96.79%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Tonix Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media prefer ATYR or TNXP?

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than aTyr Pharma. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 1 mentions for aTyr Pharma. Tonix Pharmaceuticals' average media sentiment score of 0.24 beat aTyr Pharma's score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate IVVD or ATYR?

Invivyd presently has a consensus target price of $8.00, suggesting a potential upside of 748.81%. Given Invivyd's stronger consensus rating and higher possible upside, equities research analysts clearly believe Invivyd is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Which has preferable earnings & valuation, IVVD or ATYR?

Invivyd has higher revenue and earnings than aTyr Pharma. Invivyd is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invivyd $53.43M 5.20 -$52.49M -$0.33 N/A aTyr Pharma $190K 273.62 -$74.12M -$0.62 N/A

Is IVVD or ATYR more profitable?

aTyr Pharma has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% aTyr Pharma N/A -95.89% -69.67%

Does the media prefer IVVD or ATYR?

In the previous week, Invivyd had 30 more articles in the media than aTyr Pharma. MarketBeat recorded 31 mentions for Invivyd and 1 mentions for aTyr Pharma. Invivyd's average media sentiment score of 0.24 beat aTyr Pharma's score of 0.00 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend YDES or ATYR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Which has better earnings and valuation, YDES or ATYR?

YD Bio has higher earnings, but lower revenue than aTyr Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A aTyr Pharma $190K 273.62 -$74.12M -$0.62 N/A

Is YDES or ATYR more profitable?

YD Bio's return on equity of 0.00% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A aTyr Pharma N/A -95.89% -69.67%

Do analysts recommend ATYR or PEPG?

PepGen has a consensus price target of $11.50, indicating a potential upside of 260.50%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has stronger valuation and earnings, ATYR or PEPG?

aTyr Pharma has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio aTyr Pharma $190K 273.62 -$74.12M -$0.62 N/A PepGen N/A N/A -$89.65M -$1.31 N/A

Is ATYR or PEPG more profitable?

PepGen's return on equity of -51.01% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -95.89% -69.67% PepGen N/A -51.01% -43.49%

Does the media favor ATYR or PEPG?

In the previous week, aTyr Pharma and aTyr Pharma both had 1 articles in the media. PepGen's average media sentiment score of 0.86 beat aTyr Pharma's score of 0.00 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

aTyr Pharma (ATYR) Competitors

$0.53 +0.03 (+5.68%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 -0.01 (-1.13%)

As of 05:34 PM Eastern

Compare

ATYR vs. ALEC, TNXP, IVVD, YDES, and PEPG

Should you buy aTyr Pharma stock or one of its competitors? aTyr Pharma's main competitors and comparable companies include Alector (ALEC), Tonix Pharmaceuticals (TNXP), Invivyd (IVVD), YD Bio (YDES), and PepGen (PEPG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does aTyr Pharma compare to Alector?

aTyr Pharma (NASDAQ:ATYR) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

aTyr Pharma has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Alector has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Alector has a consensus price target of $3.63, indicating a potential upside of 57.61%. Given Alector's higher possible upside, analysts clearly believe Alector is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

aTyr Pharma has a net margin of 0.00% compared to Alector's net margin of -850.13%. aTyr Pharma's return on equity of -95.89% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Alector	-850.13%	-531.03%	-44.00%

In the previous week, aTyr Pharma and aTyr Pharma both had 1 articles in the media. Alector's average media sentiment score of 1.67 beat aTyr Pharma's score of 0.00 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

aTyr Pharma has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	273.62	-$74.12M	-$0.62	N/A
Alector	$21.05M	12.20	-$142.93M	-$1.10	N/A

Summary

Alector beats aTyr Pharma on 8 of the 15 factors compared between the two stocks.

How does aTyr Pharma compare to Tonix Pharmaceuticals?

aTyr Pharma (NASDAQ:ATYR) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

aTyr Pharma has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than aTyr Pharma. MarketBeat recorded 4 mentions for Tonix Pharmaceuticals and 1 mentions for aTyr Pharma. Tonix Pharmaceuticals' average media sentiment score of 0.24 beat aTyr Pharma's score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Tonix Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 96.79%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

aTyr Pharma has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Tonix Pharmaceuticals' return on equity of -68.99% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

aTyr Pharma has higher earnings, but lower revenue than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	273.62	-$74.12M	-$0.62	N/A
Tonix Pharmaceuticals	$13.11M	16.29	-$124.02M	-$12.94	N/A

Summary

Tonix Pharmaceuticals beats aTyr Pharma on 10 of the 16 factors compared between the two stocks.

How does aTyr Pharma compare to Invivyd?

Invivyd (NASDAQ:IVVD) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

aTyr Pharma has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
aTyr Pharma	N/A	-95.89%	-69.67%

Invivyd presently has a consensus target price of $8.00, suggesting a potential upside of 748.81%. Given Invivyd's stronger consensus rating and higher possible upside, equities research analysts clearly believe Invivyd is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

Invivyd has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Invivyd has higher revenue and earnings than aTyr Pharma. Invivyd is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	5.20	-$52.49M	-$0.33	N/A
aTyr Pharma	$190K	273.62	-$74.12M	-$0.62	N/A

In the previous week, Invivyd had 30 more articles in the media than aTyr Pharma. MarketBeat recorded 31 mentions for Invivyd and 1 mentions for aTyr Pharma. Invivyd's average media sentiment score of 0.24 beat aTyr Pharma's score of 0.00 indicating that Invivyd is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.4% of Invivyd shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 5.8% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Invivyd beats aTyr Pharma on 13 of the 16 factors compared between the two stocks.

How does aTyr Pharma compare to YD Bio?

YD Bio (NASDAQ:YDES) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

YD Bio has higher earnings, but lower revenue than aTyr Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
aTyr Pharma	$190K	273.62	-$74.12M	-$0.62	N/A

YD Bio's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
aTyr Pharma	N/A	-95.89%	-69.67%

61.7% of aTyr Pharma shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

In the previous week, aTyr Pharma had 1 more articles in the media than YD Bio. MarketBeat recorded 1 mentions for aTyr Pharma and 0 mentions for YD Bio. YD Bio's average media sentiment score of 0.00 equaled aTyr Pharma'saverage media sentiment score.

Company	Overall Sentiment
YD Bio	Neutral
aTyr Pharma	Neutral

Summary

aTyr Pharma beats YD Bio on 7 of the 9 factors compared between the two stocks.

How does aTyr Pharma compare to PepGen?

aTyr Pharma (NASDAQ:ATYR) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

aTyr Pharma has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, PepGen has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

aTyr Pharma has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	273.62	-$74.12M	-$0.62	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

In the previous week, aTyr Pharma and aTyr Pharma both had 1 articles in the media. PepGen's average media sentiment score of 0.86 beat aTyr Pharma's score of 0.00 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Comparatively, 1.3% of PepGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PepGen's return on equity of -51.01% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
PepGen	N/A	-51.01%	-43.49%

PepGen has a consensus price target of $11.50, indicating a potential upside of 260.50%. Given PepGen's stronger consensus rating and higher possible upside, analysts clearly believe PepGen is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

PepGen beats aTyr Pharma on 7 of the 13 factors compared between the two stocks.

Get aTyr Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATYR vs. The Competition

Export

Metric	aTyr Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$49.19M	$3.99B	$7.29B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	N/A	11.75	271.38	24.10
Price / Sales	273.62	1,398.89	638.99	90.03
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	0.77	17.26	11.18	6.40
Net Income	-$74.12M	-$22.72M	$3.46B	$348.28M
7 Day Performance	2.14%	2.89%	1.98%	0.91%
1 Month Performance	11.98%	9.74%	7.32%	5.10%
1 Year Performance	-90.09%	54.81%	24.76%	16.16%

aTyr Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATYR aTyr Pharma	0.9062 of 5 stars	$0.53 +5.7%	N/A	-90.6%	$49.19M	$190K	N/A	53
ALEC Alector	2.3506 of 5 stars	$2.05 +4.6%	$3.63 +76.8%	-6.3%	$218.85M	$21.05M	N/A	270	Gap Down
TNXP Tonix Pharmaceuticals	3.6067 of 5 stars	$12.66 -0.4%	$24.50 +93.5%	-67.0%	$217.99M	$13.11M	N/A	50	Gap Up
IVVD Invivyd	3.5319 of 5 stars	$0.74 +2.7%	$8.00 +980.4%	+91.6%	$212.38M	$53.43M	N/A	100	Gap Down
YDES YD Bio	N/A	$3.37 +13.1%	N/A	N/A	$210.95M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATYR) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

aTyr Pharma (ATYR) Competitors